

To
the Honorable
Mr. Demosthenes Bouros
President of the Pricing Committee
Ministry of Health

Cc.: Mr Marios Salmas, Alternate Minister of Health
Prof. I. Tountas, President of EOF
Mrs M. Skouroliakou, 1st Vice President of EOF
Members of the Pricing Committee

Chalandri, April 29, 2013

Dear Mr Bouros,

Further to our letter dated 26/4/2013, we would like to clarify the following:

- In no case does SFEE oppose to the pricing of new medicines. On the contrary, for 2.5 years now, marketing of new medicinal products, both innovative and generics, is a fixed request of SFEE. Nevertheless, what we also point out is that the procedure that will be followed for the pricing of new products must be the one provided for by the applicable legislation.
- If only some of the new products are priced, this will create a competitive advantage for specific companies, against the principle of equal treatment. For example, a discretionary treatment is the pricing, by priority, of generics that concern original products whose patent has expired and for which generics are not marketed and in parallel, the non-pricing of generics that concern categories of originals in which generics are already marketed and for which an application for the determination of their price has been previously filed. Another example of discretionary treatment is the reduction of the price of certain original products by 50%, whose patent has not expired, in violation of the applicable laws.

Consequently, we kindly request that the Pricing Committee proceeds with the pricing of new products, ensuring the correctness and legality of the procedure to be followed, as required by its institutional role.

Sincerely yours,

Nikos Kefalas
Vice President of SFEE/
Member of the Pricing Committee

Fotis Mangaloussis
Director General